No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AFMD240719P5000
- 0.35
- +0.05+16.67%
15min DelayClose Jul 3 13:00 ET
0.35High0.35Low
0.35Open0.30Pre Close1 Volume554 Open Interest5.00Strike Price35.00Turnover83.60%IV8.64%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type-0.4203Delta0.4440Gamma16.97Leverage Ratio-0.0109Theta-0.0010Rho-7.13Eff Leverage0.0041Vega
Intraday
- 5D
- Daily
News
Cell Therapy Developer Artiva Refiles for a $100M IPO
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating, Announces Target Price $25
Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 48.9% an
Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.
Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.
Affimed Is Maintained at Buy by Laidlaw & Co.
Affimed Is Maintained at Buy by Laidlaw & Co.
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5% o
Laidlaw Initiates Affimed NV(AFMD.US) With Buy Rating, Announces Target Price $25
Laidlaw analyst Yale Jen initiates coverage on $Affimed NV(AFMD.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 29.7% and a total